Download the notification, link given below: The National Pharmaceutical Pricing Authority (NPPA) has notified the revised ceiling price for 872 dosage forms and strength of scheduled formulations effecting the annual change of 10.77 per cent in Wholesale Price Index (WPI) for the calendar year 2021 as against 2020 vide notification No. S.O. 1499)E) dated 30-03-2022.

Download notification No. S.O. 1499(E) dated 30-03-2022

The increased ceiling prices are applicable with effect from April 1, 2022 and exclusive of goods and services tax (GST), said the Authority.

In respect of formulation where pack wise ceiling price is notified, for any other pack size manufactured, the manufacturer shall approach NPPA under para 11(3) of DPCO, 2013 for specific price approval for its formulations. In respect of any other scheduled formulation, for which ceiling price is not mentioned in the list, the manufacturer shall approach NPPA for specific price approval for its formulations.

All manufacturers of scheduled formulations, selling branded or generic or both the versions of scheduled formulations at price higher than the ceiling price (plus goods and services taxes as applicable) so fixed and notified by the government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in the list, along with goods and services taxes as applicable, if any.

All the existing manufacturers of these scheduled formulations having maximum retail price lower than the ceiling price specified in the list may revise the existing MRP of their formulations, on the basis of WPI at 10.76607% for year 2021 over 2020.

The formulation of sodium valproate includes combination of sodium valproate and valproic acid both together corresponding to sodium valproate of the stated strength.

Prices of eight packs of glucose and sodium chloride injections in packs of non-glass with special features from 22 manufacturers; and four packs of ringer lactate injection in pack having special features like self collapsibility and self-seal ability, not having air-vent and there is no chance of contamination during manufacturing, infusion or admiring levels, manufactured by 15 manufacturers were also increased based on the WPI hike, through separate orders.

It has also revised the ceiling price of bare metal stents at Rs. 9,373.03 per unit and drug eluting stents (DES) including metallic DES and bioresorbable vascular scaffold and biodegradable stents at Rs. 34,128.13 per unit, considering the WPI for the year 2021.

The manufacturers/importers of coronary stents may add goods and services taxes only if they have paid actually or if it is payable to the government on the ceiling price mentioned in the table.

Prices of acetyl salicylic acid, calcium carbonate, condoms, dapsone, etoposide, framycetin sulphate, isoniazid, medroxyprogesterone acetate and rifampicin at specific strengths and packages has also been fixed through the notification.

Price of dextrose injection, mannitol and metronidazole in specific non-glass containers from certain manufacturers has also been revised upwards.

If an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the table launches a new drug the manufacturer shall apply for prior price approval of such new drug to NPPA in Form I as specified under Schedule-II of the DPCO, 2013.

The ceiling price of heparin injection 1000IU/ml and heparin injection 5000IU/ml would not be applicable till the time another price revision by the NPPA in the backdrop of Covid-19, in June 30, 2020, is in force.

The Authority has recently extended the price revision for another six months till September 30 2022. Prices in the Covid-19 period are Rs. 24.39 for heparin injection 1000 IU for a unit of 1 ml and Rs. 60.54 for 5000 IU for a unit of 1 ml.

The price hike linked to WPI is Rs 18.11 per 1 ml of heparin injection 1000 IU/ml and Rs. 44.95 per one ml of Heparin Injection 5000 IU/ml, though it is not applicable till further orders or till September 30.

The price of oxygen inhalation in cylinders will also be applicable as per the NPPA order in the backdrop of Covid-19 pandemic, till June 30, 2022.

NDPS Act: Courts can’t declare a particular drug as ‘Manufactured Drug’ or ‘Psychotropic Substance’: High Court

Reduce GST on Medicines, Diagnostic kits & Medical instruments from 12 to 5%: Nathealth study

DGGI acts on Pharma Companies for GST evasion: These companies come…

USFDA approves Ozempic 2 mg to treat Type-II Diabetes

Sun Pharma to introduce its version of Vortioxetine in India

NPPA extends price revision of Heparin injection, LMO and Oxygen Inhalation

Local manufacturing of 35 APIs started after PLI scheme

Telangana to fill posts of 18 Drug Inspectors, 442 Pharmacists and 15 junior Analysts

NPPA updated price lists: Download

Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/2022/04/01/nppa-notifies-revised-ceiling-price-for-872-dosage-forms-march-2022/